Thu, Mar 5, 2015, 5:46 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Vical Incorporated Message Board

  • hgff101 hgff101 Feb 17, 2013 10:29 AM Flag

    Outinfront: previous phase 3

    New here, doing initial analysis. 

    Followed up on your mention of a failed phase 3 trial.   

    That was a low dose trial comparing dacarbazine vs dacarbazine + low dose Allovectin-7 from 2002.

    The differences in this current phase 3 trial:

    1.  High dose vs low dose Allovectin-7
    2. Allovectin-7 alone against chemo, vs Allovectin-7  in combination with chemo.
    3. Relaxed RECIST rules to get past the immuno 'hump'

    These differences seem to reflect the evolving understanding of immunotherapy that has developed since that failed phase 3 trial from 2002.

    Given these differences and a comparison of similarities in success factors of the trial  with the potential success of Allovectin-7, do you consider hedging your current failure thesis for this trial?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Meant to type "Given these differences and a comparison of similarities in success factors of the ---Provenge---trial  with the potential success of Allovectin-7, do you consider hedging your current failure thesis for this trial?"

 
VICL
1.03+0.02(+1.98%)Mar 5 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.